An international perspective on cardiovascular risk management: recommendations for high-risk patients

2010 ◽  
Vol 3 (2) ◽  
pp. 91
Author(s):  
D Duhot ◽  
E McGregor ◽  
Diana Gorog ◽  
C Packard
Keyword(s):  
Risk Management ◽  
Cardiovascular Risk ◽  
High Risk ◽  
International Perspective ◽  
Cardiovascular Risk Management ◽  
High Risk Patients ◽  
Risk Patients ◽  
Management Recommendations

Cardiovascular risk assessment in diabetes and pre-diabetes

ESC CardioMed ◽  
2018 ◽  
pp. 923-924
Author(s):  
Nikolaus Marx
Keyword(s):  
Risk Assessment ◽  
Cardiovascular Risk ◽  
High Risk ◽  
Target Organ Damage ◽  
Risk Scores ◽  
High Risk Patients ◽  
Patients With Diabetes ◽  
Risk Patients ◽  
Artery Disease ◽  
Very High

Patients with diabetes exhibit an increased propensity to develop cardiovascular disease with an increased mortality. Early risk assessment, especially for coronary artery disease, is important to initiate therapeutic strategies to reduce cardiovascular risk. This chapter reviews the current literature on risk scores in patients with type 1 and type 2 diabetes and summarizes the role of risk assessment based on biomarkers and different imaging strategies. Current guidelines recommend that patients with diabetes are characterized as high-risk or very high-risk patients. In the presence of target organ damage or other risk factors such as smoking, marked hypercholesterolaemia, or hypertension, patients with diabetes are classified as very high-risk patients while most other people with diabetes are categorized as high-risk patients.

scholarly journals Do doctors and patients agree on cardiovascular-risk management recommendations post-consultation? The INTERMEDE study

2011 ◽  
Vol 61 (584) ◽  
pp. e105-e111 ◽  
Author(s):  
Anne-Cécile Schieber ◽  
Michelle Kelly-Irving ◽  
Christine Rolland ◽  
Anissa Afrite ◽  
Chantal Cases ◽  
...  
Keyword(s):  
Risk Management ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Management ◽  
Management Recommendations

Flow-mediated dilatation (FMD) and prevalence of cardiovascular risk factors: the value of FMD assessment in high risk patients is limited

2014 ◽  
pp. 254-261 ◽  
Author(s):  
Katarzyna Mizia-Stec ◽  
Joanna Wieczorek ◽  
Michał Orszulak ◽  
Magdalena Mizia ◽  
Klaudia Gieszczyk-Strózik ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
High Risk ◽  
Cardiovascular Risk Factors ◽  
High Risk Patients ◽  
Flow Mediated Dilatation ◽  
Risk Patients

scholarly journals Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

2011 ◽  
Vol 29 (6) ◽  
pp. 761-770 ◽  
Author(s):  
Tiziano Barbui ◽  
Giovanni Barosi ◽  
Gunnar Birgegard ◽  
Francisco Cervantes ◽  
Guido Finazzi ◽  
...  
Keyword(s):  
High Risk ◽  
Myeloproliferative Neoplasms ◽  
Primary Myelofibrosis ◽  
International Prognostic Scoring System ◽  
High Risk Patients ◽  
Thrombosis Risk ◽  
Risk Patients ◽  
History Of ◽  
Management Recommendations ◽  
Monitoring Response

We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first- and second-line therapy, and therapy for special issues. Key questions were selected according the criterion of clinical relevance. Statements were produced using a Delphi process, and two consensus conferences involving a panel of 21 experts appointed by the European LeukemiaNet (ELN) were convened. Patients with polycythemia vera (PV) and essential thrombocythemia (ET) should be defined as high risk if age is greater than 60 years or there is a history of previous thrombosis. Risk stratification in primary myelofibrosis (PMF) should start with the International Prognostic Scoring System (IPSS) for newly diagnosed patients and dynamic IPSS for patients being seen during their disease course, with the addition of cytogenetics evaluation and transfusion status. High-risk patients with PV should be managed with phlebotomy, low-dose aspirin, and cytoreduction, with either hydroxyurea or interferon at any age. High-risk patients with ET should be managed with cytoreduction, using hydroxyurea at any age. Monitoring response in PV and ET should use the ELN clinicohematologic criteria. Corticosteroids, androgens, erythropoiesis-stimulating agents, and immunomodulators are recommended to treat anemia of PMF, whereas hydroxyurea is the first-line treatment of PMF-associated splenomegaly. Indications for splenectomy include symptomatic portal hypertension, drug-refractory painful splenomegaly, and frequent RBC transfusions. The risk of allogeneic stem-cell transplantation–related complications is justified in transplantation-eligible patients whose median survival time is expected to be less than 5 years.

Accuracy of Anthropometric Parameters in Identification of High-risk Patients Predicted With Cardiovascular Risk Models

2013 ◽  
Vol 346 (1) ◽  
pp. 26-31 ◽  
Author(s):  
Alireza Esteghamati ◽  
Mostafa Mousavizadeh ◽  
Sina Noshad ◽  
Saeed Shoar ◽  
Omid Khalilzadeh ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
High Risk ◽  
Anthropometric Parameters ◽  
Risk Models ◽  
High Risk Patients ◽  
Risk Patients

scholarly journals SPECIFICS OF ANTIHYPERTENSION THERAPY IN HYPERTENSIVES OF VARIOUS CARDIOVASCULAR RISK (BY THE REGISTRY OF CHRONIC NON-COMMUNICABLE DISEASES IN TYUMENSKAYA OBLAST)

2018 ◽  
Vol 17 (3) ◽  
pp. 4-10
Author(s):  
A. Yu. Efanov ◽  
Yu. A. Vyalkina ◽  
Yu. A. Petrova ◽  
Z. M. Safiullina ◽  
O. V. Abaturova ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
High Risk ◽  
Risk Group ◽  
High Risk Group ◽  
Risk Level ◽  
Moderate Risk ◽  
High Risk Patients ◽  
Risk Patients ◽  
Very High

Aim. To assess the specifics of antihypertension therapy (AHT) in hypertensives of various cardiovascular risk, in the registry of chronic non-communicable diseases in Tyumenskaya oblast.Material and methods. A random sample studied, of 1704 patients with hypertension, inhabitants of Tyumenskaya oblast (region), ascribed to dispensary follow-up. Mean age 62±7,5 y.o. Of those 31,5% (n=537) males. The prevalence and efficacy of AHT assessed according to cardiovascular risk level. The significance was evaluated with the criteria χ2.Results. AHT was characterized by the growth of the frequency of treatment approaches with cardiovascular risk consideration. Regular treatment took 33,9% patients of low and moderate risk vs 41,3% of high and very high (p<0,01). In the male group such tendency also took place. Gender specifics of AHT was characterized by that in the groups of high and very high risk females took medications significantly more commonly than males — 46,6% vs 29,1% in high risk group (p<0,01) and 47,5% vs 30% in very high risk group (p<0,01). With the increase of the risk level, there was decline of treatment efficacy — from 95% in low risk group to 32,5% in very high risk group; 53,1% of the participants were taking monotherapy, 32,9% — two drugs, 14,0% — ≥3 drugs. With the increase of risk grade there is tendency to increase of combinational AHT, however with no significant increase of efficacy. Treatment efficacy in high and very high risk patients comparing to patients with low and moderate risk was significantly lower — 33,1% vs 69,7% (p<0,01), respectively. Statins intake among the high and very high risk patients was 10,6-11,0% males and 7,8% females (p<0,05).Conclusion. AHT in hypertensives in Tymenskaya oblast, under dispensary follow-up, is characterized by insufficient usage of combinational drugs. With the raise of cardiovascular risk there is tendency to higher rate of combinational AHT. However there is no significant increase in efficacy of treatment with the increase of medications number. A very low rate of statins intake is noted. The obtained specifics witness for the necessity to optimize AHT among the high and very high risk patients — inhabitants of Tyumenskya oblast.

Sign in / Sign up

Export Citation Format

Share Document